{"owner": "ArrayExpress Uploader", "ownerprofile_id": "arrayexpress_sid", "species": "human", "factors": [{"GSM969458": {"TREATMENT PROTOCOL": "under hormone depleted conditions", "PASSAGES": "not specified", "CELL LINE": "LNCaP-abl (abl) prostate cancer cells", "VARIATION": "transfected with control siRNA", "CHIP ANTIBODY": "not specified"}}, {"GSM969459": {"TREATMENT PROTOCOL": "under hormone depleted conditions", "PASSAGES": "not specified", "CELL LINE": "LNCaP-abl (abl) prostate cancer cells", "VARIATION": "depleted of EZH2", "CHIP ANTIBODY": "not specified"}}, {"GSM969458": {"TREATMENT PROTOCOL": "under hormone depleted conditions", "PASSAGES": "not specified", "CELL LINE": "LNCaP-abl (abl) prostate cancer cells", "VARIATION": "transfected with control siRNA", "CHIP ANTIBODY": "not specified"}}, {"GSM969459": {"TREATMENT PROTOCOL": "under hormone depleted conditions", "PASSAGES": "not specified", "CELL LINE": "LNCaP-abl (abl) prostate cancer cells", "VARIATION": "depleted of EZH2", "CHIP ANTIBODY": "not specified"}}, {"GSM969458": {"TREATMENT PROTOCOL": "under hormone depleted conditions", "PASSAGES": "not specified", "CELL LINE": "LNCaP-abl (abl) prostate cancer cells", "VARIATION": "transfected with control siRNA", "CHIP ANTIBODY": "not specified"}}, {"GSM969459": {"TREATMENT PROTOCOL": "under hormone depleted conditions", "PASSAGES": "not specified", "CELL LINE": "LNCaP-abl (abl) prostate cancer cells", "VARIATION": "depleted of EZH2", "CHIP ANTIBODY": "not specified"}}, {"GSM969464": {"TREATMENT PROTOCOL": "in the presence of DHT", "PASSAGES": "not specified", "CELL LINE": "LNCaP prostate cancer cells", "VARIATION": "transfected with control siRNA", "CHIP ANTIBODY": "not specified"}}, {"GSM969465": {"TREATMENT PROTOCOL": "in the presence of DHT", "PASSAGES": "not specified", "CELL LINE": "LNCaP prostate cancer cells", "VARIATION": "depleted of EZH2", "CHIP ANTIBODY": "not specified"}}, {"GSM969464": {"TREATMENT PROTOCOL": "in the presence of DHT", "PASSAGES": "not specified", "CELL LINE": "LNCaP prostate cancer cells", "VARIATION": "transfected with control siRNA", "CHIP ANTIBODY": "not specified"}}, {"GSM969465": {"TREATMENT PROTOCOL": "in the presence of DHT", "PASSAGES": "not specified", "CELL LINE": "LNCaP prostate cancer cells", "VARIATION": "depleted of EZH2", "CHIP ANTIBODY": "not specified"}}, {"GSM969464": {"TREATMENT PROTOCOL": "in the presence of DHT", "PASSAGES": "not specified", "CELL LINE": "LNCaP prostate cancer cells", "VARIATION": "transfected with control siRNA", "CHIP ANTIBODY": "not specified"}}, {"GSM969465": {"TREATMENT PROTOCOL": "in the presence of DHT", "PASSAGES": "not specified", "CELL LINE": "LNCaP prostate cancer cells", "VARIATION": "depleted of EZH2", "CHIP ANTIBODY": "not specified"}}], "id": 4535, "pop_total": 0, "platform": 4, "summary_wrapped": "This SuperSeries is composed of the SubSeries listed below. Refer to individual Series", "pubmed_id": 23239736, "geo_gse_id": "E-GEOD-39461", "owner_profile": "/profile/8773/arrayexpressuploader", "factor_count": 5, "sample_count": 12, "tags": [], "lastmodified": "Dec.12, 2014", "is_default": false, "geo_gds_id": "", "slug": "role-of-prc2-complex-components-in-prostate-cancer", "geo_id_plat": "E-GEOD-39461_A-AFFY-44", "name": "Role of PRC2 complex components in prostate cancer cell lines", "created": "Sep.19, 2014", "summary": "This SuperSeries is composed of the SubSeries listed below. Refer to individual Series", "source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-39461", "sample_source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-39461/samples/"}